Nucleus-Targeting Manganese Dioxide Nanoparticles Coated with the Human Umbilical Cord Mesenchymal Stem Cell Membrane for Cancer Cell Therapy

ACS Appl Mater Interfaces. 2023 Mar 1;15(8):10541-10553. doi: 10.1021/acsami.3c01176. Epub 2023 Feb 14.

Abstract

Recently, development of drug delivery systems for accurate delivery of antitumor drugs to tumor sites to improve their antitumor efficacy has attracted great interest in the area of cancer immunotherapy. In this report, an intelligent biodegradable hollow manganese dioxide (HMnO2) nanoparticle (NP) with a human umbilical cord mesenchymal stem cell (hUC-MSC) membrane coating was designed to exert efficient chemo-immunotherapy for cancer treatment. A TAT peptide-modified membrane structure was constructed for nuclear targeting. Our findings showed that this new nanoreactor inherited the active targeting capability of MSCs and exhibited tumoritropic accumulation significantly at the cancerous parts. Compared with other formulations, intravenous injection of the NPs markedly inhibited tumor growth, relapse, and metastasis. Moreover, we found that the NPs effectively boosted dendritic cell maturation and recruited effector T cells into tumors. Overall, this work demonstrates the great potential of applying MSC membrane-coated manganese dioxide NPs as nucleus-targeting nanocarriers in cancer chemo-immunotherapy.

Keywords: biomimetic delivery platforms; manganese dioxide; mesenchymal stem cell; nuclear-targeted; tumor immunotherapy.

MeSH terms

  • Humans
  • Mesenchymal Stem Cells*
  • Nanoparticles* / chemistry
  • Neoplasms* / metabolism
  • Umbilical Cord

Substances

  • manganese dioxide